


G.Pasterkamp UMCU





Age corrected death rate cardiovascular disease in the Netherlands





Atherosclerosis: current concept





Large lipid Thin cap Thrombus formation pool








Stable plaque Vulnerable plaque

<u>Plaque</u> <u>rupture</u>








Davies et al.







Nature Reviews | Cardiology











J Am Coll Cardiol. 2015 Mar 3;65(8):846-55. doi: 10.1016/j.jacc.2014.11.041. Epub 2015 Jan 16.

The myth of the "vulnerable plaque": transitioning from a focus on individual lesions to atherosclerotic disease burden for coronary artery disease risk assessment.

Arbab-Zadeh A¹, Fuster V².


Author information

- 1 Department of Medicine, Cardiology Division, Johns Hopkins University, Baltimore, Maryland. Electronic address: azadeh1@jhmi.edu.
- 2 Mount Sinai Medical Center, Icahn School of Medicine, New York, New York.

Abstract

The cardiovascular science community has pursued the quest to identify vulnerable atherosclerotic plaque in patients for decades, hoping to prevent acute coronary events. However, despite major advancements in imaging technology that allow visualization of rupture-prone plaques, clinical studies have not demonstrated improved risk prediction compared with traditional approaches. Considering the complex relationship between plaque rupture and acute coronary event risk suggested by pathology studies and confirmed by clinical investigations, these results are not surprising. This review summarizes the evidence supporting a multifaceted hypothesis of the natural history of atherosclerotic plaque rupture. Managing patients at risk of acute coronary events mandates a greater focus on the atherosclerotic disease burden rather than on features of individual plaques.





HOME

ARTICLES & MULTIMEDIA *

ISSUES *

SPECIALTIES & TOPICS ~

FOR AUTHORS *



ORIGINAL ARTICLE


A Correction Has Been Published

A Prospective Natural-History Study of Coronary Atherosclerosis

Gregg W. Stone, M.D., Akiko Maehara, M.D., Alexandra J. Lansky, M.D., Bernard de Bruyne, M.D., Ecaterina Cristea, M.D., Gary S. Mintz, M.D., Roxana Mehran, M.D., John McPherson, M.D., Naim Farhat, M.D., Steven P. Marso, M.D., Helen Parise, Sc.D., Barry Templin, M.B.A., Roseann White, M.A., Zhen Zhang, Ph.D., and Patrick W. Serruys, M.D., Ph.D., for the PROSPECT Investigators*

N Engl J Med 2011; 364:226-235 | January 20, 2011 | DOI: 10.1056/NEJMoa1002358





Identified were 596 thin-cap fibroatheromas


P value

• Major adverse cardiovascular events, 26 (51.0%) were thin-cap fibroatheromas

Trends in Acute Myocardial Infarction Incidence, Detection, and Treatment


Based on the 2015 50 Top Cardiovascular Hospitals Study







Merged data from OCT and pathology studies



G Pasterkamp, H den Ruijter, P Libby. Nature reviews Cardiology 2016

Antihypertensivemedication

Lipid loweringtherapy

Smoking policyRisk factor treatment


- •STEMI
 - •NSTEMI


Total burden of ACS



•STEMI

•NSTEMI






. Nature reviews Cardiology 2016

Death rate following stroke, the Netherlands





Vaartjes et al. Stroke 2013

Athero-Express



- Collecting endarteriectomy specimen (carotid, femoral and AAA) and blood (start 2002)
- Now >4000 patients included.
- GWAS data available of 1800 patients, whole genome methylation of 700 plaques.

Athero-Express






Femoral+ iliac




• N= 1000



carotid



N= 2400



AAA



N = 600



Time-Dependent Changes in Atherosclerotic Plaque Composition in Patients Undergoing Carotid Surgery

Guus W. van Lammeren, MD, PhD*; Hester M. den Ruijter, PhD*; Joyce E.P. Vrijenhoek, MD; Sander W. van der Laan, MSc; Evelyn Velema, MSc; Jean-Paul P.M. de Vries, MD, PhD; Dominique P.V. de Kleijn, PhD; Aryan Vink, MD, PhD; Gert Jan de Borst, MD, PhD; Frans L. Moll, MD, PhD; Michiel L. Bots, MD, PhD; Gerard Pasterkamp, MD, PhD

Background—Time-dependent trends in the incidence of cardiovascular disease have been reported in high-income countries. Because atherosclerosis underlies the majority of cardiovascular diseases, we investigated temporal changes in the composition of atherosclerotic plaques removed from patients undergoing carotid endarterectomy.

Methods and Results—The Athero-Express study is an ongoing, longitudinal, vascular biobank study that includes the collection of atherosclerotic plaques of patients undergoing primary carotid endarterectomy in the province of Utrecht from 2002 to 2011. Histopathologic features of plaques of 1583 patients were analyzed in intervals of 2 years. The analysis included quantification of collagen, calcifications, lipid cores, plaque thrombosis, macrophages, smooth muscle cells, and microvessels. Large atheroma, plaque thrombosis, macrophages, and calcifications were less frequently observed over time, with adjusted odds ratios of 0.72 (95% confidence interval, 0.650-0.789), 0.62 (95% confidence interval, 0.569-0.679), 0.87 (95% confidence interval, 0.800-0.940), and 0.75 (95% confidence interval, 0.692-0.816) per 2-year increase in time, respectively. These changes in plaque characteristics were consistently observed in patient subgroups presenting with stroke, transient ischemic attack, ocular symptoms, and asymptomatic patients. Concomitantly, risk factor management and secondary prevention strategies among vascular patients scheduled for carotid endarterectomy significantly improved over the past decade.

Conclusions—In conclusion, over the past decade, atherosclerotic plaques harvested during carotid endarterectomy show a time-dependent change in plaque composition characterized by a decrease in features currently believed to be causal for plaque instability. This appears to go hand in hand with improvements in risk factor management. (Circulation. 2014;129:2269-2276.)


Key Words: endarterectomy, carotid ■ histology ■ plaque, atherosclerotic ■ primary prevention



Plaque composition	2002-2003 n=250	2004-2005 n=408	2006-2007 n=352	2008-2009 n=332	2010-2010 n=271
> 40% lipid (%)	33	36	27	21	14*
Intra plaque bleeding (%)	74	75	62	49	37*
Vessel density (AU)	6.7	8.5	7.7	7.3	6.3


Intra plaque bleeding over time






Calcification over time










Lammeren et al. Circulation 2014


Femoral artery plaques (% of plaques)






If underlying pathology is shifting: implications University Med








- In the presence of (a)symptomatic disease: much more stable lesions are observed.
- For increasing number of patients: Are we still chasing the right target, e.g. the "vulnerable plaque"?
- What does this imply for tissue and plasma biobanks (biomarkers): Do data and samples obtained before 2000 still represent current patient population?

Patients undergoing carotid endarterectomy University Medical Center Utrecht










Governmental policy in the Netherlands: smoking banned from public areas since 2004.




All organs and cells share the same DNA



But how the genetic information is used differs to the leach organ
























Athero-Express

Are plaque characteristics determined by genetic architecture?




vet

UMC Utrecht Hart- en vaatcentrum

University Medical Center Utrecht


Associations of 57 Cardiovascular Risk Loci with atherosclerotic plaque traits





Questions

◆ To what extent do the 57 known CAD susceptibility loci correlate with (vulnerable) plaque characteristics?



19 out of 57 CAD risk variants associate with a plaque characteristic $a \sim 6.5$ -fold enrichment, $p = 3.8 \times 10^{-11}$ University Medical Center Utrecht

Phenotype	Locus	OR[[95%[CI]	Р	Disease	GWASidir.
Calcification	WDR12	0.7440.5830.94]	0.012	CAD	+
Calcification	ZNF259-APOA5-APOA1	1.2641.0184.58]	0.043	CAD	+
Calcification	LDLR	1.5941.2132.07]	6.29x10 ⁻⁴	CAD	-
Calcification	KCNE2¶geneddesert)	0.7140.5540.91]	7.92x10 ⁻³	CAD	-
Collagen	NOS3	1.7341.03322.90]	0.031	CAD	-
Collagen	SMG6	0.7840.6430.95]	0.012	CAD	-
Fat	MIA3	1.2741.0241.56]	0.029	CAD	+
Fat	ZEB2-ACO74093.1	1.3841.0041.92]	0.049	CAD	-
Fat	7q22	0.6340.5140.77]	5.09x10 ⁻⁶	CAD	-
Fat	NOS3	1.7341.03822.90]	0.031	CAD	-
Fat	TRIB1	0.7740.6540.92]	3.54x10 ⁻³	CAD	-
Fat	ABO	1.27ᆌ1.02월71.59]	0.034	CAD	-
IPH	LIPA	1.2741.07871.52]	6.33x10 ⁻³	CAD	-

Phenotype	Locus	β፬[s.e.m.]	Р	Disease	GWASadir.
Macrophages	BCAS3	-0.137頃0.054]	0.011	CAD	-
SMCs	LIPA	0.08340.040]	0.036	CAD	-
SMCs	COL4A1/A2	0.103톈0.042]	0.015	CAD	-
Vessels	SWAP70	0.079톈0.040]	0.046	CAD	+
Vessels	KSR2	0.109@0.040]	6.97x10 ⁻³	CAD	-
Vessels	UBE2Z	-0.080 ₫ 0.038]	0.034	CAD	-




Variant rs12539895 on 7q22 is associated with **less intraplaque fat content** (OR = 0.63, A-allele)


Same allele associated with decreased susceptibility for CAD (OR = 0.96)

Most significant:

chr7:106,901,393:I:D, TG > T in the intron of COG5 (OR = 0.52 [0.40-0.66 95% CI] per A-allele, p = 2.14x10⁻⁷, CAF= 0.17)














Methylation: no transcription












Case: the hunger study




- Winter 1944-1945
 - 3.5 million people
 - 20.000 deaths



Case: the Hongerwinter studie





Normal birthweight

low birthweight



Case: the Hongerwinter studie






Later age: obesity +


Normal weight





- Genetische code is bij een individu hetzelfde in ieder orgaan
- Maar of de code wordt "afgeschreven", is niet hetzelfde per orgaan of cel.







Atlana Evonasa, da una stata venesadin



beenvaten



• N= 1000



halsslagader



• N= 2300



aneurysma



N= 600




DNA methylation: smoking






DNA methylatian in plaques: smoking






Epigenetic gene transcription regulation







•DNA-methylation only occurs at Cytosine-Guanine (CpG)

•DNA-methylation is cell type specific



Next step: did methylation of DNA in plaques change in non smokers after banning smokers in public areas?



